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Abstract
Background: HMGA2 expression has been shown to be associated with enhanced selective
chemosensitivity towards the topoisomerase (topo) II inhibitor, doxorubicin, in cancer cells.
Although the roles of signaling cascades and proteins as regulatory factors in development,
neoplasia and adaptation to the environment are becoming well established, evidence for the
involvement of regulatory small RNA molecules, such as microRNAs (miRNAs) as important
regulators of both transcriptional and posttranscriptional gene silencing is presently mounting.
Results: Here we report that HMGA2 expression in head and neck squamous cell carcinoma
(HNSCC) cells is regulated in part by miRNA-98 (miR-98). Albeit HMGA2 is associated with
enhanced selective chemosensitivity towards topoisomerase (topo) II inhibitor, doxorubicin in
HNSCC, the expression of HMGA2 is thwarted by hypoxia. This is accompanied by enhanced
expression of miRNA-98 and other miRNAs, which predictably target HMGA2. Moreover, we
show that transfection of pre-miR-98™ during normoxia diminishes HMGA2 and potentiates
resistance to doxorubicin and cisplatin. These findings implicate the role of a miRNA as a key
element in modulating tumors in variable microenvironments.
Conclusion: These studies validate the observation that HMGA2 plays a prominent role in
governing genotoxic responses. However, this may only represent cells growing under normal
oxygen tensions. The demonstration that miRNA profiles are altered during hypoxia and repress
a genotoxic response indicates that changes in microenvironment in eukaryotes mimic those of
lower species and plants, where, for example, abiotic stresses regulate the expression of thousands
of genes in plants at both transcriptional and posttranscriptional levels through a number of
miRNAs and other small regulatory RNAs.
Background
High mobility group A2 (HMGA2) protein is a non-his-
tone architectural transcription factor, which is a member
of the HMGA family. This family is constituted by
HMGA1a, HMGA1b, HMGA1c, and HMGA2[1,2].
HMGAs are chromosomal proteins that bind through
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their AT binding motifs or AT hooks to the minor groove
of AT-rich DNA strands[3]. The two types of HMGA pro-
tein, HMGA1 (HMG-I/Y) and HMGA2 (HMGI-C), have
similar functions and are coded for by two different genes
at chromosomal loci 6p21.3 and 12q15, respectively.
HMGA proteins are expressed predominantly during
embryogenesis, their expression being absent or greatly
reduced in adult tissues [4,5]. However, HMGA proteins
have been implicated in the regulation of transcription,
differentiation, neoplastic transformation, and integra-
tion and expression of viral genomes [6,7]. HMGA2 has
been implicated mainly in benign and malignant mesen-
chymal tumors[8] Nevertheless, increased expression of
HMGA2 in oral squamous cell carcinoma has been linked
to epithelial-mesenchymal transition, whereby epithelial
cells acquire mesenchymal characteristics [8]. Addition-
ally, HMGA2 expression in patients with breast cancer has
been shown to be associated with poor prognosis and
metastasis [9]. However, the precise role of and the molec-
ular events elicited by HMGA2 in tumorigenesis still need
to be defined. Furthermore, HMGA2 expression has been
shown to be associated with enhanced selective chemo-
sensitivity towards the topoisomerase (topo) II inhibitor,
doxorubicin, in breast cancer HS578T and salivary Pa-4/
HMGA2 cells [2]. These studies have suggested that
HMGA2 induces a persistent basal H2AX Ser139 phos-
phorylation and perturbs doxorubicin-elicited DNA dam-
age checkpoint promoting enhanced chemosensitivity
towards doxorubicin treatment in HMGA2-expressing
cells.
Although proteins have been established as regulatory fac-
tors in growth, development and accommodation to alter-
ations in environment, our knowledge of the contribution
of regulatory small RNA molecules to such is rapidly
evolving [10]. MicroRNAs (miRNAs) are 20–24 nucle-
otide non-coding RNA molecules that post-transcription-
ally control gene expression. They are spawned by RNA
polymerase II as large primary miRNA (pri-miRNA) tran-
scripts [11,12]. Some miRNAs are structured in clusters
and transcribed as polycistrons [13], while others exist in
introns of protein-coding genes [14] and are co-tran-
scribed with host genes. Pri-miRNA transcripts form typi-
cal fold-back structures that are identified and processed
into ~70nt imperfect stem-loop miRNA precursors (pre-
miRNAs) by a microprocessor complex [15,16]. After
processing by the microprocessor complex, pre-miRNAs
are exported by Ran-GTP dependent transporter exportin-
5 [17-19] from the nucleus into cytoplasm, where they are
processed by the RNAse III enzyme, Dicer, into imperfect
dsRNA duplexes that contain both mature and comple-
mentary miRNA strands [20-22]. One of the mature
miRNA strands forms an effector ribonucleoprotein com-
plex termed RISC (RNA induced silencing complex)
which guides the miRNAs to specific mRNAs [23]. RISC
either cleaves or blocks translation of the target mRNA,
depending on the degree of sequence complementarity.
Here we report that HMGA2 expression in head and neck
squamous cell carcinoma (HNSCC) cells is regulated in
part by the expression of miRNA-98 (miR-98). Albeit
HMGA2 is associated with enhanced selective chemosen-
sitivity towards topoisomerase (topo) II inhibitor, doxo-
rubicin in HNSCC, the expression of HMGA2 is thwarted
by hypoxia. This is accompanied by enhanced expression
of miRNA-98 and other miRNAs, which predictably target
HMGA2. Moreover, we show that transfection of pre-miR-
98™ during normoxia diminishes HMGA2 and potenti-
ates resistance to doxorubicin and cisplatin. These find-
ings implicate the role of a miRNA as a key element in
modulating tumors in variable microenvironments.
Materials and methods
Cell cultures
All experiments were performed using established cell
lines, including primary human oral squamous cell carci-
noma (SCC) cell lines from the American Type Culture
Collection (SCC-4 and SCC-9), and the UMB-10B cell line
(UMB). SCC cell lines were cultured in 1:1 mix of Ham's
F12 and Dulbecco's Modified Eagle's Medium (DMEM)
with 10% fetal bovine serum, 100 units of penicillin, 100
μg/ml streptomycin and 0.4 g/ml of hydrocortisone
(Sigma Chemical Company). Cell lines were subcultured
using a disaggregration assay with Trypsin (0.1%) and
EDTA (0.01%) in phosphate buffered saline (PBS) pH
7.5. For some experiments cell lines were made hypoxic
by placing them in a Heto-Holten Cell house incubator at
1% O2, 5% CO2 and 94% nitrogen for periods up to 1 hr
or 5% O2, 5% CO2 and 90% nitrogen for periods up to 8
hr. All agents were administered by syringe in a closed sys-
tem for hypoxia experiments to avoid reoxygenation
effects. The oxygen levels for all systems were monitored
using an Instech FO/SYS21OT micro oxygen monitoring
system (Instech Labs., Inc.).
Antibodies
Polyclonal monospecific mouse anti-HMGA2 antibody
was obtained from ABNOVA. Monoclonal anti-actin anti-
body was from Chemicon. HRP-goat-antimouse second-
ary antibody was obtained from Kirkegaard & Perry Labs.
Inc.
RNA isolation, labeling and miRNA microarray
For these studies RNA was obtained using mirVana™
miRNA Isolation Kit (Ambion). The levels and quality of
RNA was achieved by the Agilent Bioanalyzer™ and with a
spectrophotometer using 230 nm/260 nm ratios. The
dendrimer Cy3 and Cy5 dyes were then employed to label
RNA sequences. First, poly-A tails were added to the RNA
sequences at 3' ends using poly(A) polymerase. A nucle-Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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otide tag was then added to the poly-A tail in a ligation
reaction. In the case of dual-sample experiments, the two
sets of RNA sequences were added with tags of two differ-
ent sequences. The tagged RNA sequences were hybridized
to the array with labeling carried out during the second
hybridization reaction using dendrimer dyes. The labeled
samples were then hybridized over night to a
Human_V7.1C_051017 miRNA array chip (LC Sciences)
using a micro circulation pump. After the hybridization,
the chips were subjected to a stringent wash and fluores-
cence data were collected by using an Axon laser scanner
model 4000B (Axon Instruments) and the chips were
scanned at a pixel size of 10 μM with Cy3 Gain at 460 and
the Cy5 Gain at 470 scanning. Data extraction and image
process were performed using ArrayPro™ software
equipped with a morphological filter (Media Cybernet-
ics).
Selection of plausible miR targets
To select plausible targets to validate the significance of
the detected miRs  we utilized 1) miRNA viewer [24],
which is based on miRanda software for miRNA predica-
tion of potential targets (The default parameters were set
at Gao Open Penalty:-8.0; Gap Extend: -2.0; Score Thresh-
old: 50.0: Energry Threshold -20.0 kCal/mol; Scaling
Parameter: 2.0) 2) miRBase Targets from the Sanger Insti-
tute, 3) TargetScanS, and 4) PicTar, which identifies both
binding-sites targeted by single microRNA, as well as
those that are co-regulated by several microRNAs in a
coordinated manner. In that miRNAs may have a multi-
tude of conserved miRNA:UTR pairs, recognizing that
hypoxia has been associated with drug resistance, the gen-
eral principle for these studies was to seek possible target
genes that influenced DNA repair, drug action, or resist-
ance.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assays for measurement of cell viability
For these studies, cell lines were seeded into 24-well plates
to obtain a confluence of 50–60% on the day of the exper-
iment. The cell lines were treated with various reagents of
indicated concentration and medium was changed daily
for 3 days. Twenty-four to seventy-two hours after the start
of treatment (depending on the cell line), 50 μl of 5 mg/
mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT; Roche) in OptiMEM I (Invitrogen)
was added to each well and the plate was incubated at
37°C for an additional 4 hours and 10% SDS in .01 M
HCl was added to each well to dissolve the formazan crys-
tals. Absorbance was immediately read at 575 nm in a
scanning multiwell spectrophotometer. The results were
depicted as percentage of cell viability, reported as the
mean ± SD of three independent experiments done in
triplicate.
Protein lysate preparation and Western blot analysis
The cell lines were plated in 6-well plates using a density
of 5 × 104cells/well and were allowed to grow to 80% con-
fluence. The cell lines were washed twice with cold PBS,
lysed in RIPA buffer (50 mM Tris [pH 7.4], 150 mM NaCl,
1% Triton X-100, 1% deoxycholic acid, sodium salt, 0.1%
sodium dodecyl sulfate [SDS], 100 μg/ml phenylmethyl-
sulfonyl fluoride, 1 μg/ml aprotinin, 1 mM dithiothreitol
and 1 mM sodium orthovanadate) for 10 min and
scraped. The extracts were centrifuged at 40,000 g for 15
min at 4°C. Protein concentrations were measured and
equalized using Bio-Rad protein assay (Bio-Rad Laborato-
ries) according to the manufacturer's instructions. Equiv-
alent amounts of protein (50 μg) were then separated by
SDS-PAGE and then transferred to polyvinylidene difluo-
ride membranes. Equivalent loading was confirmed by
staining membranes with Ponceau-S. The membranes
were blocked for 1 h in blocking buffer (1× Tris-buffered
saline, 5% nonfat dry milk, and 0.1% Tween 20), which
was subsequently replaced by the primary antibody in
blocking buffer, overnight at 4°C. After incubation, the
membranes were washed three times in washing buffer
(1× Tris-buffered saline and 0.1% Tween 20). Primary
antibody was detected using horseradish peroxidase-
linked goat antimouse (Kirkegaard & Perry Labs. Inc.) or
goat antirabbit IgG antibody (Kirkegaard & Perry Labs.
Inc.) and visualized with SuperSignal West Pico chemilu-
minescent substrate. To validate loading of the gels the
membranes were washed with PBS/Tween, treated with a
stripping buffer (20 mMDTT, 2% SDS, 67.5 mM Tris, pH
6.7) rewashed with PBS/Tween, blocked with 10% non-
fat dried milk, incubated with anti-β-actin antibodies and
developed as described above. The bands were scanned
and quantified using NIH image software.
Transfection of small interfering RNA
For transient transfection, cell lines were seeded at 90%
confluency, and transfections were carried out by using
Lipofectamine 2000 (Invitrogen) according to the instruc-
tions of the manufacturer. The oligonucleotides encoding
HMGA2 small interfering RNA (siRNA) were 5'-CAG-
CAATCTGTCGCTAAGGdTdT-3' and 5'-CCTTAGCGACA-
GATTGCTGdTdT-3'. In some studies SCC cell lines grown
in D-MEM (GIBCO) supplemented with 10% fetal bovine
serum (GIBCO) were transfected with 15 or 5 pmol of
Pre-miR-98™ or negative control 1 Precursor miRNAs
(Ambion) in 24-well plates using siPort Neo-FX™
(Ambion) according to the manufacturer's protocol.
Three days posttransfection, cell lines were analyzed for
viability and by Western blot. To study the effects of Anti-
miR-98™, cell lines grown as above were transfected in 24-
well plates with 30 pmol of Anti-miR-98™ or negative con-
trol 1 inhibitors (Ambion) using Lipofectamine 2000.
Three days post transfection the cell lines were analyzed
by vitality asays, by Northern blot and Western blot.Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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Reverse transcription-PCR for HMGA2 and miRNA-98 and 
Northern blot validation of miRNA-98
RNA was extracted using Trizol reagent (Invitrogen)
according to the protocols of the manufacturer followed
by DNA-free DNase treatment (Ambion, Austin, TX). Sub-
sequent cDNA synthesis and PCR reactions were carried
out using ThermoScript reverse transcription-PCR (RT-
PCR) System (Invitrogen). The following primer pairs
were used for PCR reaction: HMGA2, 5'-
GTGAGCCCTCTCCTAAGAGAC-3' and 5'-CTGCAGT-
GTCTTCTCCCTTC-3'; glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), 5'-GACCACAGTCCATGCCATCAC-
3' and 5'-CATACCAGGAAATGAGCTTGAC-3'. To validate
miRNA by PCR, RNA was extracted with the mirVana™
miRNA Isolation Kit and the miRVana qRT-PCR miRNA™
Detection kit for miRNA-98 and 5S (Ambion). The levels
of miRNA-98 were determined using mirVana™ Probe
with oligonucleotide positive controls; 5S rRNA and an
RNA probe specific for miR-16 miRNA following the
manufactures protocols.
Statistical analysis
Statistical analyses utilized two-tailed Student's test; statis-
tical significance was set as p ≤ 0.05.
Results and discussion
Poor oxygenation (hypoxia) is present in the majority of
human tumors and is associated with poor prognosis due
to the protection it affords to radiotherapy and chemo-
therapy [25]. Here, we sought first to verify the chemore-
sistance effect of hypoxia to doxorubicin and cisplatin in
SCC cell lines, comparing cell lines grown in normoxic
and hypoxic atmospheres. These studies revealed all SCC
cell lines studied here using MTT cell vitality responded in
a dose-dependent manner to doxorubicin. Moreover,
when the cell lines were grown under hypoxic conditions,
they demonstrated enhanced cell viability (Figure 1). Sim-
ilar results were also observed for cisplatin (not shown).
The mechanisms for chemoresistance to these agents
under hypoxia were initially unclear. Existing knowledge
dictates that tumors cope with hypoxic microenviron-
ments by bringing forth multiple cellular response path-
ways that alter gene expression and affect tumor
progression by strongly suppressing the rates of mRNA
translation during hypoxia [25].
Although the roles of signaling cascades and proteins as
regulatory factors in development, neoplasia and adapta-
tion to the environment are becoming well established,
the evidence for involvement of regulatory small RNA
molecules as important regulators of both transcriptional
and posttranscriptional gene silencing is presently mount-
ing [10]. Thus, in the present study we grew SCC cell lines
both in a normoxic atmosphere and in an environment
that mimics the hypoxia encountered in solid head and
neck tumors and used differential display hybridization to
a human miRNA chip, and Real-time RT-PCR and North-
ern blot validation, to discern miRNA expression profiles.
SCC cells that were grown under hypoxic conditions dif-
ferentially expressed 47 miRNA genes compared to cells
grown under normoxic conditions (P < 0.04). The follow-
ing miRNAs were expressed to the greatest extent during
hypoxia:hsa-miRNA-572, -214, -563, -637, -628, -191, -
210, -498, -373, -98, -148b, -15a, -148-a, -200a, -30b, -
429, -7, hsa-let-7e, -7i, and -7g (Table 1). Conversely, the
following miRNAs were most diminished in their expres-
sion in hypoxic cells: hsa-miRNA-122a, -565, -195, -30e-
5p, -374, -19a, -101, -424, -29b, -186, -141, -320, -422b,
and -197 (Table 1).
One of the most prevalent changes in expression profiles
involved a 4.56 fold increased expression of hsa-miR-98.
To validate these findings we grew SCC cell lines in either
a normoxic or hypoxic environment as before and
assessed the miRNA-98 levels with miRVana qRT-PCR
miRNA™ Detection kit. These studies revealed that follow-
ing hypoxia the relative levels of miRNA-98 increased
among the SCC cell lines in an oxygen dependent manner
(Figure 2). These changes in miRNA-98 were validated in
Chemosensitivity towards doxorubicin of SCC cell lines Figure 1
Chemosensitivity towards doxorubicin of SCC cell 
lines. Percent cell viability following doxorubicin treatment 
to assess chemosensitivity towards doxorubicin was meas-
ured by MTT assays. SCC cell lines were grown under nor-
moxic (Ќ SCC-4, ■ SCC-10B and  SCC-9) or hypoxic (● 
SCC-4, ❍ SCC-10B, and ▼ SCC-9) conditions and treated 
with various concentrations of doxorubicin. Significant differ-
ences between cell lines grown under hypoxic conditions and 
normoxic conditions was detected for all three cell lines as 
determined by two-tailed Student's t test (p ≤ 0.05). The 
error bars represent the S.E.M. for 3 experiments.Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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Northern blot analyses using mirVana miR-98™ Probe,
normalized to 5S rRNA (not shown).
To further appraise the role of miRNA-98 during nor-
moxia and hypoxia SCC cell lines were transfected with
the pre-miR-98™ or anti-miR-98™ (Ambion) using
siPORT™ NeoFX™ Transfection Agent, for 72 hours. The
predicted changes in the levels of miRNA-98 were vali-
dated by miRVana qRT-PCR™ as before (not shown). SCC
cell lines transfected with either anti-miR-98™ or with pre-
miR-98™ were then challenged with varying doses of dox-
orubicin and the surviving fraction of cells as a percentage
of control was determined using the MTT assay. Cell lines
grown in normoxic conditions revealed greater percent of
surviving cells when treated with pre-miR-98™ compared
to controls and anti-miR-98™ transfected cell lines. There
was no significant difference between cell lines treated
with anti-miR-98™ and controls. Cell lines grown under
hypoxic conditions and transfected with pre-miR-98™
showed a slight increase in surviving cells compared to
control cells and anti-miR-98™ transfected cell lines. There
was no significant difference between control and anti-
miR-98™ transfected cell lines (Figure 3a). Similar find-
ings were also extended to other double-strand breaks
elicited by cisplatin in SCC cells (Figure 3b). These studies
revealed that normoxic cell lines treated with pre-miR-
98™ acquired chemoresistance to doxorubicin and cispla-
tin.
Next, we sought to assess potential targets for miRNA-98
that might explain the observed chemoresistance to these
drugs during hypoxia or in pre-miR-98™ transfected nor-
moxic cell lines. In that miRNA-98 has 487 conserved
miRNA:UTR pairs within the human genome by miRNA
viewer, we selected potential targets that were predicted
Relative expression of miRNA-98 in normoxia and hypoxia Figure 2
Relative expression of miRNA-98 in normoxia and 
hypoxia. The relative levels of miRNA-98 were determined 
using the mirVana™ miRNA Isolation Kit and the miRVana 
qRT-PCR miRNA™ Detection kit for miR-98 and 5S 
(Ambion, Austin, TX). Cell lines were grown under nor-
moxic or hypoxic (5% O2 and 1% O2) conditions. The differ-
ences between cell lines grown under normoxic condition 
were significantly different to those grown at 1% O2 with a P 
≤ 0.05. The error bars represent S.E.M. for 3 experiments.
Table 1: miRNAs differentially expressed following hypoxia in SCC cells.
miRNAs Hypoxia Up-regulated miRNAs Hypoxia Down-regulated
hsa-miRNA-572 6.16 hsa-miRNA-122a -13.54
hsa-miRNA-214 5.39 hsa-miRNA-565 - 6.77
hsa-miRNA-563 517 hsa-miRNA-195 - 6.36
hsa-miRNA-637 4.96 hsa-miRNA-30e-5p - 5.93
hsa-miRNA-98 4.56 hsa-miRNA-374 - 4.17
hsa-miRNA-628 4.50 hsa-miRNA-19a - 3.95
hsa-miRNA-191 4.19 hsa-miRNA-101 - 3.73
hsa-miRNA-210 4.16 hsa-miRNA-424 - 3.68
hsa-miRNA-31 3.97 hsa-miRNA-186 - 3.63
hsa-miRNA-498 2.94 hsa-miRNA-29b - 3.66
hsa-miRNA-373 2.85 hsa-miRNA-148b - 3.48
hsa-miRNA-19a 2.46 hsa-miRNA-141 - 3.05
hsa-miRNA-148a 2.30 hsa-miRNA-22 - 2.10
hsa-miRNA-15a 2.28 hsa-miRNA-331 - 2.02
hsa-miRNA-200a 2.20 hsa-miRNA-422b - 2.01
hsa-miRNA-7 2.20 hsa-miRNA-197 - 2.00
hsa-miRNA-30b 2.19
hsa-let-7e 2.26
hsa-let-7g 2.22
hsa-let-7i 2.12
SCC cells that were grown under hypoxic conditions differentially expressed 47 miRNA genes compared to cells grown under normoxic conditions 
(P < 0.04). Data represent the fold changes in miRNA expression. hsa-miRNA-98 represents the 5th most highly expressed miRNA during hypoxia.Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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from at least two of the database resources with at least
two miRNA target sites. Utilizing miRNA viewer, the high
mobility group protein HMGI-C (High mobility group
AT-hook 2, HMGA2) was one of the highest ranking genes
with five potential target sites for hsa-miRNA-98. Utilizing
other databases it was found that PicTar defined 6 hsa-
miRNA-98 target sites, and TargetScanS identified 7 hsa-
miRNA-98  target sites (Figure 4). Notable was that a
number of other miRNAs included in the hypoxia profile
also were potential regulators for HMGA2. Most prevalent
a. Cell viability of doxorubicin treated SCC cell lines following pretreatment with anti-miR-98™ and pre-miR-98™ Figure 3
a. Cell viability of doxorubicin treated SCC cell lines following pretreatment with anti-miR-98™ and pre-miR-
98™. The SCC-4 cell line was grown under normoxia or hypoxia and transfected with anti-miR-98™ or pre-miR-98™. The 
cell line was then challenged with varying doses of doxorubicin as described in Methods. The surviving fraction of cells as a per-
centage of control was determined using the MTT assay. Cell lines grown in normoxic conditions revealed greater percent of 
surviving cells when treated with pre-mir-98™ (●) compared to controls (▼) and anti-miR-98™ (❍) transfected cells. (p ≤ 
0.05). There was no significant difference between cell lines treated with anti-miR-98™ and controls. Cell lines grown under 
hypoxic conditions and transfected with pre-miR-98™ (Ќ) showed a slight increase in surviving cells compared to control cell 
lines (■) and Anti-miR-98™ () transfected cell lines (p ≤ 0.05). There was no significant difference between control and anti-
miR-98™ transfected cell lines. Similar results were observed for SCC-9 and SCC-10B cell lines. The error bars represent 
S.E.M. for 3 experiments. b. Cell viability of cisplantin treated cell lines following pretreatment with anti-miR-98™ 
and pre-miR-98™. The SCC-4 cell line was grown under normoxic or hypoxic conditions and transfected with anti-miR-
98™ while others were transfected with pre-miR-98™. The cell line was then challenged with varying doses of cisplatin as 
described in Methods. The surviving fraction of cells as a percentage of control was determined using the MTT assay. Cells 
grown in normoxic conditions revealed greater percent of surviving cells when treated with pre-mir-98™ (▼) compared to 
controls (●) and anti-miR-98™ (Ќ) transfected cell lines (p ≤ 0.05). There was no significant difference between cells treated 
with anti-miR-98™ and controls. Cell lines grown under hypoxic conditions and transfected with pre-miR-98™ (■) showed no 
significant difference in the percent of surviving cells compared to control cells (❍) and Anti-miR-98™ () transfected cell 
lines. Likewise, there was no significant difference between control and anti-miR-98™ transfected cell lines. Similar results 
were observed for SCC-9 and SCC-10B cell lines. The error bars represents S.E.M. for 3 experiments.Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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among this later group utilizing TargetScanS were hsa-let-
7g which possessed 7 target sites for HMGA2 (Figure 5),
hsa-let-7e with 7 target sites (Figure 6) and hsa-let-7i with
7 sites (Figure 7). Albeit, the expression of has-let-7g, -7i,
and -7i was similar to miRNA-98, being low in normoxia,
but increasing following hypoxia (Table 1).
Recognizing that HMGA2 has been shown to perturb dox-
orubicin-elicited DNA damage checkpoint control and to
promote enhanced chemosensitivity towards doxorubicin
and cisplatin treatment in HMGA2-expressing breast can-
cer cells [2], we assessed whether hypoxia altered the
expression of HMGA2; SCC cell lines were subjected to
hypoxia, harvested and the expression of HMGA2 was
determined by Western blot. These studies revealed that
hypoxia diminished the levels of HMGA2 protein expres-
sion (Figure 8a).
To verify that HMGA2 potentiated genotoxic stress in SCC
cell lines we paralleled our studies to those performed in
breast cancer cells [2]. In essence, cell lines were trans-
fected with siRNA oligonucleotides for HGMA2 as
described above. The oligonucleotides encoding HMGA2
siRNA was compared with an oligonucleotide scramble
siRNA as control [2]. These studies revealed that HMGA2
siRNA induced down-regulation of HMGA2 protein
expression as assessed by Western blot (Figure 8b lower
panel), and diminished doxorubicin sensitivity by MTT
assays (Figure 8c). Recognizing that SCC cell lines became
resistant to doxorubicin during periods of hypoxia and
following diminished HMGA2 expression after siRNA
transfection in normoxic cells we sought to verify that
HMGA2 was a feasible target for miRNA-98 in SCC cell
lines. To further appraise HMGA2 as a miRNA-98 target,
SCC cell lines were transfected with the pre-miR-98™
(Ambion) using siPORT™ NeoFX™ Transfection Agent, for
72 hours. The increased levels of miRNA-98 were vali-
dated by miRVana qRT-PCR™ as before. These treatments
resulted in diminishment in protein levels and mRNA
expression of HMGA2 in control the normoxic SCC-4 cell
line as well as cell lines exposed to hypoxia (Figure 9a,b);
similar results were obtained for SCC-10B and SCC-9 cell
lines (not shown). The demonstration that pre-miRNA-
98™ diminished mRNA expression of HMGA2 was sur-
prising, since the tenet of early studies, using reporter con-
structs had indicated that complete complementarities
between miRNAs and target mRNAs was necessary for
cleavage, whereas mismatches result in translational
repression. However, the findings reported here are sup-
ported by more recent research, which revealed that miR-
NAs with partial complementarities can induce
attenuation in cognate transcript levels [26-29]. In fact,
most recently it has been shown that the ability of miR-
NAs to expedite poly(A) removal does not result from
TargetScanS miRNA98 target sites for HMGA2 Figure 4
TargetScanS miRNA98 target sites for HMGA2. In addition to 7mer sites, TargetScanS predicts 8mer sites defined as: 
An exact match to positions 2–8 of the mature miRNA (the seed + position 8) with a downstream 'A' across from position 1 
of the miRNA. In addition to 8mer sites, TargetScanS predicts 7mer sites of two types: 7mer-m8: An exact match to positions 
2–8 of the mature miRNA (the seed + position 8) and 7mer-1A: An exact match to positions 2–7 of the mature miRNA (the 
seed) with a downstream 'A' across from position 1 of the miRNA.Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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decreased translation; nor does translational repression
by miRNAs require a poly(A) tail, with a 3' histone stem-
loop being an effective substitute [30].
Conversely, the use of the anti-miR-98™ provided little
information in the present studies. Cell lines grown under
normoxia express little miRNA-98 so that the effects of
TargetScanS has-let-7e target sites for HMGA2 Figure 6
TargetScanS has-let-7e target sites for HMGA2. In addition to 7mer sites, TargetScanS predicts 8mer sites defined as: 
An exact match to positions 2–8 of the mature miRNA (the seed + position 8) with a downstream 'A' across from position 1 
of the miRNA. In addition to 8mer sites, TargetScanS predicts 7mer sites of two types: 7mer-m8: An exact match to positions 
2–8 of the mature miRNA (the seed + position 8) and 7mer-1A: An exact match to positions 2–7 of the mature miRNA (the 
seed) with a downstream 'A' across from position 1 of the miRNA.
TargetScanS has-let-7g target sites for HMGA2 Figure 5
TargetScanS has-let-7g target sites for HMGA2. In addition to 7mer sites, TargetScanS predicts 8mer sites defined as: 
An exact match to positions 2–8 of the mature miRNA (the seed + position 8) with a downstream 'A' across from position 1 
of the miRNA. In addition to 8mer sites, TargetScanS predicts 7mer sites of two types: 7mer-m8: An exact match to positions 
2–8 of the mature miRNA (the seed + position 8) and 7mer-1A: An exact match to positions 2–7 of the mature miRNA (the 
seed) with a downstream 'A' across from position 1 of the miRNA.Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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anti-mir-98™ on HMGA2 levels were limited (Figure
9a,b). Transfection with anti-miR-98™ had only minor
effects on the HMGA2 levels in SCC cell lines grown in
hypoxia (Figure 9a,b). This is probably owing to the
increased expression during hypoxia of other targeting
miRNAs such as hsa – let-7g, hsa-let-7e and hsa-let-7i all of
which possess 7 complementary target sites for HMGA2.
Inherent in these findings is the recognition that derepres-
sion of a mRNA targeted by a miRNAs in an altered micro-
environment probably can not be achieved through
down-regulation of a single miRNA in that most mRNAs
possess multiple complementary target sites with a
number of miRNAs.
Until lately, there was only speculation that inhibition by
a miRNA to a specific mRNA could be effectively reversed.
However, recent studies have shown that CAT-1 mRNA
and reporters bearing its 3'UTR can be relieved from miR-
122-mediated repression in human Huh7 hepatoma cells
when they are subjected to different types of stress. More-
over, that the derepression is accompanied by the release
of CAT-1 mRNA from cytoplasmic processing bodies and
its entry into polysomes and that the process involves
binding of HuR, trans-acting AU rich element (ARE) bind-
ing protein, to the 3'UTR of CAT-1 mRNA [31]. There is
also additional evidence indicating that some miRNA-
controlled mRNAs can be relieved from repression by syn-
aptic stimulation [32,33] indicating that miRNA regula-
tion is more pronounced than previously anticipated and
that it is able to respond quickly to specific cellular needs.
What is yet to be determined is whether changes in oxygen
tension provide a like mechanism for derepression of
miRNAs against HMGA2. There is clear evidence that
HuR, a major ARE-binding protein is expressed in many
different cells and regulates the stability, subcellular shut-
tling, and/or translation of ARE-mRNAs (reviewed [34]).
Moreover, the level of cytoplasmic HuR increases during
cell proliferation, differentiation, and in response to stress
stimuli [35-38] decreasing with senescence [39]. Also, the
high level of cytoplasmic HuR in cancer cells is in keeping
with the ability of HuR to increase the stability and trans-
lation of ARE-mRNAs that regulate cell proliferation and
neovascularization by stabilizing VEGF following
hypoxia. HuR has also been shown to shuttle between
nucleus and cytoplasm during hypoxia and to stabilize
HIF-1α and EGFR mRNAs [34]. Consequently, we
searched the AERD database [40] but were not able to
demonstrate any of the five clusters containing adenylate
uridiylate (AU)-rich elements in their 3'-untranslated
region (3'-UTR) that would afford HMGA2 stabilization
or derepression by HuR. Furthermore, since HuR shuttles
from the nucleus to the cytoplasm during hypoxia it
would appear that HMGA2 would be overwhelmed by
HuR, making it unlikely that HMGA mRNA is stabilized
like other ARE-mRNAs.
Conclusion
These studies validate the observation that HMGA2 plays
a prominent role in governing genotoxic responses. How-
ever, this may only represent cells growing under normal
TargetScanS has-let-7i target sites for HMGA2 Figure 7
TargetScanS has-let-7i target sites for HMGA2. In addition to 7mer sites, TargetScanS predicts 8mer sites defined as: 
An exact match to positions 2–8 of the mature miRNA (the seed + position 8) with a downstream 'A' across from position 1 
of the miRNA. In addition to 8mer sites, TargetScanS predicts 7mer sites of two types: 7mer-m8: An exact match to positions 
2–8 of the mature miRNA (the seed + position 8) and 7mer-1A: An exact match to positions 2–7 of the mature miRNA (the 
seed) with a downstream 'A' across from position 1 of the miRNA.Molecular Cancer 2007, 6:5 http://www.molecular-cancer.com/content/6/1/5
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oxygen tensions. The demonstration that miRNA profiles
are altered during hypoxia and repress a genotoxic
response indicates that changes in microenvironment in
eukaryotes mimic lower species and plants, where, for
example, abiotic stresses regulate the expression of thou-
sands of genes in plants at both transcriptional and post-
transcriptional levels through a number of miRNAs and
other small regulatory RNAs[41]. Yet to be established is
to what extent miRNA expression is regulated by defined
signaling cascades and transcription factors.
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